tislelizumab,sorafenib
beigene,bayer,novartis
['tislelizumab', 'sorafenib', 'hcc']
frontline tislelizumab demonstrates noninferior os vs sorafenib in unresectable hcc #esmo2022 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.